SAN DIEGO, September 12, 2022 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, clinically integrated solutions. Procedural, today announced that it will continue its partnership with the Scoliosis Research Society (SRS) as a Double Diamond Sponsor and attend the 57e Annual meeting held September 14-17, 2022 in stockholmSweden.
“SRS is a leading company in our industry, and we share a common vision to support research and education efforts to advance care for all patients with spinal deformities,” said Chris Barry, CEO of NuVasive. “It is clear that procedures integrated with enabling technology are essential in larger and more complex deformity cases, and our partnership with SRS helps us strengthen our ability to move the standard of spine surgery to solutions. smarter.”
As part of the SRS Annual Meeting, NuVasive will host a workshop titled “Over a Decade of MAGEC®: results and effectiveness thanks to real-world data and experiments” presented by Professor Kenneth CheungTeacher Ralf D. Stückerand dr. Paul Godfather, and moderated by Dr. Amer Samdani on September 15, 2022. This case-based discussion will cover the impact of the MAGEC system on the panel’s early-onset scoliosis patients and their practices over the past 10 years. NuVasive Senior Vice President of Scientific Affairs, Kyle Malonewill also share a brief scientific update on the MAGEC system.
NuVasive has partnered with SRS, the premier international company dedicated to fostering optimal care for all patients with spinal deformities, since 2007. The company’s ongoing Double Diamond sponsorship supports clinical workshops, hands-on training, as well as fellowships and grants for more than 1,500 of the world’s leading spine surgeons, researchers, medical assistants and orthotists involved in the research and treatment of spinal deformities.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care and change lives. The company’s less invasive and procedurally integrated surgical solutions are designed to provide reproducible, clinically proven results. The company’s comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, surgical planning software, navigation and imaging solutions, adjustable implant systems magnetic spine and orthopedics, as well as intraoperative neuromonitoring technologies and services. With over $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals and patients. For more information, visit www.nuvasive.com.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if not materialized or prove to be incorrect, could cause NuVasive results to differ. materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that contribute to the uncertain nature of these statements include, among others, the risks associated with the acceptance of the Company’s surgical products and procedures by spine surgeons and hospitals, the development and acceptance of new products or product improvements, clinical and statistical verification of the benefits obtained from the use of NuVasive’s products, the Company’s ability to adequately manage inventory as it continues to introduce new products, its ability to recruit and retain management and key personnel; and other risks and uncertainties described in NuVasive’s press releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive undertakes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date on which it was made.